TIMP-1 increases expression and phosphorylation of proteins associated with drug resistance in breast cancer cells.

Tissue inhibitor of metalloproteinase 1 (TIMP-1) is a protein with a potential biological role in drug resistance. To elucidate the unknown molecular mechanisms underlying the association between high TIMP-1 levels and increased chemotherapy resistance, we employed SILAC-based quantitative mass spectrometry to analyze global proteome and phosphoproteome differences of MCF-7 breast cancer cells expressing high or low levels of TIMP-1. In TIMP-1 high expressing cells, 312 proteins and 452 phosphorylation sites were up-regulated. Among these were the cancer drug targets topoisomerase 1, 2A, and 2B, which may explain the resistance phenotype to topoisomerase inhibitors that was observed in cells with high TIMP-1 levels. Pathway analysis showed an enrichment of proteins from functional categories such as apoptosis, cell cycle, DNA repair, transcription factors, drug targets and proteins associated with drug resistance or sensitivity, and drug transportation. The NetworKIN algorithm predicted the protein kinases CK2a, CDK1, PLK1, and ATM as likely candidates involved in the hyperphosphorylation of the topoisomerases. Up-regulation of protein and/or phosphorylation levels of topoisomerases in TIMP-1 high expressing cells may be part of the mechanisms by which TIMP-1 confers resistance to treatment with the widely used topoisomerase inhibitors in breast and colorectal cancer.

[1]  N. Brünner,et al.  Association of tissue inhibitor of metalloproteinases-1 and Ki67 in estrogen receptor positive breast cancer , 2013, Acta oncologica.

[2]  I. Gromova,et al.  Proteomic Profiling of Triple-negative Breast Carcinomas in Combination With a Three-tier Orthogonal Technology Approach Identifies Mage-A4 as Potential Therapeutic Target in Estrogen Receptor Negative Breast Cancer* , 2012, Molecular & Cellular Proteomics.

[3]  R. Peto,et al.  Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. , 2012, Lancet.

[4]  K. L. Sharpe-Timms,et al.  TIMP1 Contributes to Ovarian Anomalies in Both an MMP-Dependent and -Independent Manner in a Rat Model1 , 2012, Biology of reproduction.

[5]  S. Zahler,et al.  Tissue inhibitor of metalloproteinase-1 (TIMP-1) regulates mesenchymal stem cells through let-7f microRNA and Wnt/β-catenin signaling , 2012, Proceedings of the National Academy of Sciences.

[6]  Y. Yen,et al.  Inhibitors of mTOR overcome drug resistance from topoisomerase II inhibitors in solid tumors. , 2011, Cancer letters.

[7]  J. Olsen,et al.  Global Phosphoproteome Profiling Reveals Unanticipated Networks Responsive to Cisplatin Treatment of Embryonic Stem Cells , 2011, Molecular and Cellular Biology.

[8]  M. Mann,et al.  Quantitative, high-resolution proteomics for data-driven systems biology. , 2011, Annual review of biochemistry.

[9]  L. Jianhua,et al.  A fine balance between CCNL1 and TIMP1 contributes to the development of breast cancer cells. , 2011, Biochemical and biophysical research communications.

[10]  T. Wang,et al.  Tissue inhibitor of metalloproteinase-1 decreased chemosensitivity of MDA-435 breast cancer cells to chemotherapeutic drugs through the PI3K/AKT/NF-кB pathway. , 2011, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[11]  Stefan Wölfl,et al.  Real-Time Monitoring of Cisplatin-Induced Cell Death , 2011, PloS one.

[12]  R. Gjerset,et al.  Protein kinase CK2 is a central regulator of topoisomerase I hyperphosphorylation and camptothecin sensitivity in cancer cell lines. , 2011, Biochemistry.

[13]  H. Nielsen,et al.  Plasma TIMP-1 levels and treatment outcome in patients treated with XELOX for metastatic colorectal cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  Trey Ideker,et al.  Cytoscape 2.8: new features for data integration and network visualization , 2010, Bioinform..

[15]  David S. Wishart,et al.  DrugBank 3.0: a comprehensive resource for ‘Omics’ research on drugs , 2010, Nucleic Acids Res..

[16]  Damian Szklarczyk,et al.  The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored , 2010, Nucleic Acids Res..

[17]  Tudor I. Oprea,et al.  ChemProt: a disease chemical biology database , 2010, Nucleic Acids Res..

[18]  J. Baselga.  Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. , 2011, The oncologist.

[19]  H. Nielsen,et al.  Preoperative plasma TIMP-1 is an independent prognostic indicator in patients with primary colorectal cancer: a prospective validation study. , 2010, European journal of cancer.

[20]  Dirk Repsilber,et al.  ExprEssence - Revealing the essence of differential experimental data in the context of an interaction/regulation net-work , 2010, BMC Systems Biology.

[21]  Ying-Hsuan Wang,et al.  Organogenesis and tumorigenesis: Insight from the JAK/STAT pathway in the Drosophila eye , 2010, Developmental dynamics : an official publication of the American Association of Anatomists.

[22]  Nils Brünner,et al.  HER2, TOP2A, and TIMP-1 and responsiveness to adjuvant anthracycline-containing chemotherapy in high-risk breast cancer patients. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  Xiongfei Zhang,et al.  Tissue inhibitor of metalloproteinase‐1 protects MCF‐7 breast cancer cells from paclitaxel‐induced apoptosis by decreasing the stability of cyclin B1 , 2010, International journal of cancer.

[24]  K. Gevaert,et al.  Improved visualization of protein consensus sequences by iceLogo , 2009, Nature Methods.

[25]  Matthias Mann,et al.  A Dual Pressure Linear Ion Trap Orbitrap Instrument with Very High Sequencing Speed* , 2009, Molecular & Cellular Proteomics.

[26]  N. Brünner,et al.  Lack of TIMP-1 tumour cell immunoreactivity predicts effect of adjuvant anthracycline-based chemotherapy in patients (n=647) with primary breast cancer. A Danish Breast Cancer Cooperative Group Study. , 2009, European journal of cancer.

[27]  L. Martiny,et al.  TIMP-1 binding to proMMP-9/CD44 complex localized at the cell surface promotes erythroid cell survival. , 2009, The international journal of biochemistry & cell biology.

[28]  M. Mann,et al.  Global and site-specific quantitative phosphoproteomics: principles and applications. , 2009, Annual review of pharmacology and toxicology.

[29]  B. Maček,et al.  High accuracy mass spectrometry in large-scale analysis of protein phosphorylation. , 2009, Methods in molecular biology.

[30]  Jürgen Cox,et al.  A practical guide to the MaxQuant computational platform for SILAC-based quantitative proteomics , 2009, Nature Protocols.

[31]  J. Cardelli,et al.  TIMP-1 overexpression promotes tumorigenesis of MDA-MB-231 breast cancer cells and alters expression of a subset of cancer promoting genes in vivo distinct from those observed in vitro , 2009, Breast Cancer Research and Treatment.

[32]  M. Mann,et al.  MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification , 2008, Nature Biotechnology.

[33]  M. Mann,et al.  Comprehensive mass-spectrometry-based proteome quantification of haploid versus diploid yeast , 2008, Nature.

[34]  N. Rajewsky,et al.  Widespread changes in protein synthesis induced by microRNAs , 2008, Nature.

[35]  P. Bork,et al.  Linear Motif Atlas for Phosphorylation-Dependent Signaling , 2008, Science Signaling.

[36]  W. Stetler-Stevenson.  Tissue Inhibitors of Metalloproteinases in Cell Signaling: Metalloproteinase-Independent Biological Activities , 2008, Science Signaling.

[37]  D. Loegering,et al.  Mitotic Phosphorylation Stimulates DNA Relaxation Activity of Human Topoisomerase I* , 2008, Journal of Biological Chemistry.

[38]  Xiaoqi Liu,et al.  Plk1-dependent Phosphorylation Regulates Functions of DNA Topoisomerase IIα in Cell Cycle Progression* , 2008, Journal of Biological Chemistry.

[39]  C. Britten,et al.  G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer , 2008, British Journal of Cancer.

[40]  H. Nielsen,et al.  Comparative studies of tissue inhibitor of metalloproteinases-1 in plasma, serum and tumour tissue extracts from patients with primary colorectal cancer , 2008, Scandinavian journal of gastroenterology.

[41]  M. Mann,et al.  Higher-energy C-trap dissociation for peptide modification analysis , 2007, Nature Methods.

[42]  Stephen L. Abrams,et al.  Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. , 2007, Biochimica et biophysica acta.

[43]  H. Nielsen,et al.  TIMP-1 Is Significantly Associated with Objective Response and Survival in Metastatic Colorectal Cancer Patients Receiving Combination of Irinotecan, 5-Fluorouracil, and Folinic Acid , 2007, Clinical Cancer Research.

[44]  James E. Ferrell,et al.  Mechanisms of specificity in protein phosphorylation , 2007, Nature Reviews Molecular Cell Biology.

[45]  P. Bork,et al.  Systematic Discovery of In Vivo Phosphorylation Networks , 2007, Cell.

[46]  I. Trougakos,et al.  Development of resistance to chemotherapeutic drugs in human osteosarcoma cell lines largely depends on up‐regulation of clusterin/apolipoprotein J , 2007, International journal of cancer.

[47]  N. Brünner,et al.  Primary Tumor Levels of Tissue Inhibitor of Metalloproteinases-1 Are Predictive of Resistance to Chemotherapy in Patients with Metastatic Breast Cancer , 2006, Clinical Cancer Research.

[48]  M. Mann,et al.  Global, In Vivo, and Site-Specific Phosphorylation Dynamics in Signaling Networks , 2006, Cell.

[49]  N. Brünner,et al.  TIMP-1 gene deficiency increases tumour cell sensitivity to chemotherapy-induced apoptosis , 2006, British Journal of Cancer.

[50]  Xu-wen Liu,et al.  Identification of CD63 as a tissue inhibitor of metalloproteinase‐1 interacting cell surface protein , 2006, The EMBO journal.

[51]  T. Deguchi,et al.  Expression of clusterin, XIAP and survivin, and their changes by camptothecin (CPT) treatment in CPT-resistant PC-3 and CPT-sensitive LNCaP cells. , 2006, Experimental oncology.

[52]  M. Mann,et al.  Parts per Million Mass Accuracy on an Orbitrap Mass Spectrometer via Lock Mass Injection into a C-trap*S , 2005, Molecular & Cellular Proteomics.

[53]  N. Brünner,et al.  Tissue inhibitor of metalloproteinases-1 in breast cancer. , 2005, Endocrine-related cancer.

[54]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[55]  H. Nielsen,et al.  Establishment and Characterization of 7 New Monoclonal Antibodies to Tissue Inhibitor of Metalloproteinases-1 , 2005, Tumor Biology.

[56]  N. Brünner,et al.  Measurement of the Uncomplexed Fraction of Tissue Inhibitor of Metalloproteinases-1 in the Prognostic Evaluation of Primary Breast Cancer Patients* , 2005, Molecular & Cellular Proteomics.

[57]  Bonnie F. Sloane,et al.  Tissue inhibitor of metalloproteinase-1 protects human breast epithelial cells from extrinsic cell death: a potential oncogenic activity of tissue inhibitor of metalloproteinase-1. , 2005, Cancer research.

[58]  C. Luparello,et al.  Tissue inhibitor of metalloprotease (TIMP)‐1 and proliferative behaviour of clonal breast cancer cells , 1999, Breast Cancer Research and Treatment.

[59]  Xu-wen Liu,et al.  Tissue Inhibitor of Metalloproteinase-1 Protects Human Breast Epithelial Cells Against Intrinsic Apoptotic Cell Death via the Focal Adhesion Kinase/Phosphatidylinositol 3-Kinase and MAPK Signaling Pathway* , 2003, Journal of Biological Chemistry.

[60]  E. Nishida,et al.  Identification of a Consensus Motif for Plk (Polo-like Kinase) Phosphorylation Reveals Myt1 as a Plk1 Substrate* , 2003, Journal of Biological Chemistry.

[61]  N. Brünner,et al.  Tumor Tissue Concentrations of the Proteinase Inhibitors Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) and Plasminogen Activator Inhibitor Type 1 (PAI-1) Are Complementary in Determining Prognosis in Primary Breast Cancer * , 2003, Molecular & Cellular Proteomics.

[62]  M. Mann,et al.  Stable Isotope Labeling by Amino Acids in Cell Culture, SILAC, as a Simple and Accurate Approach to Expression Proteomics* , 2002, Molecular & Cellular Proteomics.

[63]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[64]  E. Nishida,et al.  Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase , 2001, Nature.

[65]  G. Li,et al.  Tissue inhibitor of metalloproteinase-1 inhibits apoptosis of human breast epithelial cells. , 1999, Cancer research.

[66]  J. Keski‐Oja,et al.  Expression of collagenases-1 and -3 and their inhibitors TIMP-1 and -3 correlates with the level of invasion in malignant melanomas , 1999, British Journal of Cancer.

[67]  U. Thorgeirsson,et al.  Tissue inhibitor of metalloproteinases-1 (TIMP-1) binds to the cell surface and translocates to the nucleus of human MCF-7 breast carcinoma cells. , 1999, Biochemical and biophysical research communications.

[68]  H. Nielsen,et al.  Quantitation of TIMP-1 in plasma of healthy blood donors and patients with advanced cancer , 1999, British Journal of Cancer.

[69]  V. Dixit,et al.  Bcl-x and Bcl-2 inhibit TNF and Fas-induced apoptosis and activation of phospholipase A2 in breast carcinoma cells. , 1995, Oncogene.

[70]  K. Iwata,et al.  Growth‐promoting activity of tissue inhibitor of metalloproteinases‐1 (TIMP‐1) for a wide range of cells A possible new growth factor in serum , 1992, FEBS letters.

[71]  N. Osheroff,et al.  Phosphorylation of DNA topoisomerase II by casein kinase II: modulation of eukaryotic topoisomerase II activity in vitro. , 1985, Proceedings of the National Academy of Sciences of the United States of America.